白癜风早期系统干预:一项前瞻性双中心介入研究
这项前瞻性双中心介入研究纳入51例白癜风患者,按病程和活动性分为三组,均接受窄谱UVB和口服小剂量激素每周两次治疗6个月。结果显示新诊断组(<6个月)VES75达标率46%,显著高于长病程伴新发皮损组16%和长病程稳定组0%,提示早期系统治疗存在机会窗口。
要点
- 新诊断白癜风患者早期系统治疗6个月,46%达到VES75。
- 长病程稳定患者VES75为0%,长病程伴新发皮损为16%。
- 表皮成熟黑素细胞在早期组50%存在,长病程稳定组无。
核心结论
- 早期系统治疗使新诊断白癜风患者获得显著更好的复色反应,提示存在早期机会窗口。
研究设计与样本
- 前瞻性双中心介入研究,51例 eligible 患者按病程和活动性分为三组,均接受Nb-UVB和口服小剂量激素每周两次治疗6个月。
主要发现
- 治疗6个月VES75达标率:G1组0%,G2组16%,G3组46%(p=0.01)。
- 表皮成熟黑素细胞存在比例:G3组50%,G2组20%,G1组0%。
- 所有患者病灶皮肤均残留黑素细胞前体。
关键数值与推荐
- VES75定义为较基线白斑面积改善75%。
- 分组标准:G1长病程(>2年)无活动皮损;G2长病程伴近期皮损;G3新诊断(<6个月)伴活动皮损。
临床怎么用
- 对新诊断且活动性白癜风患者应尽早启动系统治疗,可能提高复色率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitiligo is a complex autoimmune skin disease characterized by loss of melanocytes resulting in the appearance of white skin patches. Recent advances in treatment have improved patient outcomes, but the process of repigmentation is prolonged and often incomplete. OBJECTIVES: To evaluate the effects of early systemic intervention in newly diagnosed vitiligo patients compared to those with a longer disease duration, including both long-standing and recently developed depigmented lesions, on clinical outcome, melanocytes and melanocyte precursor reservoir at lesional sites across groups. METHODS: Prospective bicentric interventional study. Fifty-one eligible patients were enrolled in three groups depending on duration and activity of their vitiligo (G1: long-lasting disease (more than 2 years) with no active lesions; G2: long-lasting disease with recent lesions; G3: newly diagnosed, less than 6 months, with active lesions). All subjects received Nb-UVB and oral mini pulse of corticosteroids twice a week for 6 months. Clinical scores were used to assess extent (VES) and disease activity (V-SAS). Primary objective was to compare efficacy of treatment at 6 months between the groups. Secondary objectives include the analysis of melanocyte and melanocyte precursor reservoir using skin immunohistofluorescence of lesional vitiligo skin. RESULTS: Of 51 randomized patients, 44 (86%) completed the 6-month assessment. Mean disease duration was 13.4 years in G1, 8.3 years in G2 and 4.8 months in G3. VES75 (75% improvement from baseline extent of vitiligo) at 6 months after treatment was achieved in 0% in G1, 16% in G2 and 46% in G3 (p = 0.01). Epidermal mature melanocytes persisted in 50% of G3 patients, 20% of G2 and none of the G1 patients. All patients had remaining melanocyte precursors in the lesional skin. CONCLUSIONS: Early systemic therapeutic approach allows a significantly better response in recently diagnosed patients, highlighting the importance of an early window of opportunity in vitiligo. Vitiligo is an autoimmune skin condition in which the immune system attacks pigment‐producing cells, called melanocytes, causing the appearance of white patches on the skin. Although treatments have improved, repigmentation often takes a long time and is sometimes incomplete. This study investigated whether early treatment leads to better outcomes than treating people who have been affected for longer. Fifty‐one adults were enrolled and grouped according to how long they had had vitiligo and whether the disease was active: (G1) long‐standing stable disease, (G2) long‐standing disease with new recent patches and (G3) newly diagnosed disease within 6 months. All participants were administered the same combination treatment for 6 months, consisting of narrowband UVB phototherapy plus low‐dose oral corticosteroids twice weekly. Improvement was measured using clinical scores for extent and activity, and skin samples were analysed to assess remaining melanocytes and precursor cells. After 6 months, people treated promptly after diagnosis exhibited the best outcomes: 46% of subjects in the early intervention group demonstrated a repigmentation level of at least 75%, in contrast to the 16% of those with long‐standing disease and recent lesions, and 0% of those with long‐standing stable disease. Mature melanocytes were more frequently still present in early lesions, while precursor cells were found across all groups. These findings suggest that there is a ‘window of opportunity’ during the early stages of vitiligo, wherein systemic treatment can result in substantially better repigmentation.
引用
- Bertold C, Seneschal J, Fontas E, et al. Early systemic intervention for vitiligo: A prospective bicentric interventional study. J Eur Acad Dermatol Venereol. 2026. PMID: 42788257. doi:10.1111/jdv.70748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。